Sign inJoin waitlistJoin the waitlist

YY

Yuanquan Yang

Physician · Ohio State University College of Medicine

Credentials: · · · · · · ·

History

Ohio State University College of Medicine
2020–Present

Roswell Park Comprehensive Cancer Center
2015–2018
Internal Medicine
Albert Einstein College of Medicine of Yeshiva University
2012–2015
Tongji Medical College
2001–2005

Research

Neoadjuvant Atezolizumab With Gemcitabine and Cisplatin in Patients With Muscle-Invasive Bladder Cancer: A Multicenter, Single-Arm, Phase II Trial
Journal of Clinical Oncology · 2022 · 94 citations
High intratumoral CD8+ T-cell infiltration is associated with improved survival in prostate cancer patients undergoing radical prostatectomy
The Prostate · 2021 · First of 8 authors · 75 citations
Emerging Immunotherapy Approaches for Advanced Clear Cell Renal Cell Carcinoma
Review · Cells · 2023 · Last of 10 authors · Corresponding · 66 citations

AM
Amir Mortazavi
11 papers
Katharine Collier
11 papers
Mingjia Li
10 papers
Eric Singer
9 papers
Ming Yin
9 papers
Adam Khorasanchi
8 papers · 5 as a fellow
Lingbin Meng
8 papers · 2 as a fellow
AP
Anish Parikh
6 papers
Debasish Sundi
6 papers
PM
Paul Monk
6 papers
Shawn Dason
6 papers
Steven Clinton
6 papers

Clinical trials

Futibatinib in Combination With Durvalumab Prior to Cystectomy for the Treatment of Muscle-Invasive Bladder Cancer Patients Who Are Ineligible for Cisplatin-based Therapy
Principal investigator · Recruiting · Phase 2
Yuanquan Yang
2024–2026
Siltuximab for the Prevention of Severe Immune-Related Adverse Events During Immune Checkpoint Inhibitor Rechallenge in Patients With Advanced Cancer, CIRES Trial
Principal investigator · Recruiting · Phase 2
Yuanquan Yang
2024–2030
A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitecan-hziy Versus Standard of Care in the Treatment of Advanced Urothelial Cancer
Site PI · Recruiting · Phase 3
National Cancer Institute (NCI)
2025–2030
Testing of Bevacizumab, Erlotinib, and Atezolizumab in Combination for Advanced-Stage Kidney Cancer
Site PI · Recruiting · Phase 2
National Cancer Institute (NCI)
2022–2027